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Chemotherapy-Induced
Immunosuppression
by Lucy Rasmussen* and Ann Arvin*
Chemotherapeutic agents are used widely in clinical medicine for the treatment of conditions
where diminution of the host immune response is a goal. The clinical use of immunosuppres-
sion is indicated for immunologically mediated disease, lymphoproliferative diseases, and
prevention of graft rejection. Five categories of agents are useful for these purposes; they are
ionizing irradiation, corticosteroids, biological alkylating agents, antilymphocyte sera and
antimetabolites. While the specific molecular action of many ofthese drugs is known, how they
affect cellular events in immune responses is less clear. One of the unfortunate sequelae of
chemotherapy induced immunosuppression is an increased susceptibility of the host to
opportunistic pathogens or malignancies.
Specific methods are described for monitoring the various parameters of both humoral and
cellular immunity.
Studies of immunologic function in lymphoma patients and cardiac transplant patients
treated with immunosuppressive drugs have shown specific defects in cell mediated immunity to
herpes viruses which may relate to their increased susceptibility to infection by these agents.
Immunosuppressive Agents Used
in Clinical Medicine
The use of immunosuppressive drugs in clinical
medicine is necessary to diminish the immune
response to a point where responses to undesirable
foreign antigens are eliminated. This state of
chemically induced immunologic unresponsiveness
may have undesirable features, for example plac-
ing the host at risk of infection by a wide variety
of opportunistic agents. This review will focus on
three major areas: first, a broad review of immu-
nosuppressive agents available in clinical medicine
and clinical situations in which they are useful.
Second, specific laboratory methods for assessing
immunity will be emphasized. Last, model systems
for studying the effects of immunosuppression will
be analyzed.
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A battery ofimmunosuppressive agents is avail-
able for use in clinical medicine. These are detailed
in Table 1 along with examples of each category.
Table 1. Immunosuppressive agents available in clinical
medicine.
Agent Example
Ionizing irradiation Whole body irradiation
Extracorporeal irradiation
Corticosteroids Prednisone
Biological alkylating agents Nitrogen mustards
Cyclophosphamide
Chlorambucil, melphalan
Lymphocyte depletion by Antilymphocyte sera
thoracic duct drainage or
antilympocyte serum
Antimetabolites
Antibiotics Azaserine
Mitomycin C
Actinomycins
Chloramphenicol
Purine, pyrimidine antagonists 6-MP, azathioprine
Cytosine arabinoside
Folate antagonists Methotrexate
Alkaloids Colchicine
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FIGURE 1. Schematic representation of stages in the immune response.
In general, these forms of immunosuppression are
nonspecific and lead to diminution of response to a
wide variety ofagents. While methods ofinduction
of unresponsiveness to specific antigens are avail-
able, they generally utilize either specific antibody
or antigen. This area has been treated in detail in
excellent reviews edited by Talmage and associ-
ates (1) and will not be considered here.
The modes of action of most immunosuppressive
agents at the cellular level are complex and far
from being clear at this point. Schematically, the
events in an immune response may be divided into
"inductive" and "productive" phases. The "induc-
tive" phase involves the interaction ofantigen with
smalllymphocytes. The "productive" stageinvolves
steps resulting in the proliferation of stimulated
cells with the eventual elaboration ofproducts, for
example, antibody for humoral immunity or sensi-
tized T-lymphocyte and lymphokines for cell-
mediated immunity. Most lines of evidence sug-
gest that many immunosuppressive agents act
mainly by impairing the reproductive capacity of
immunologically competent or active cells. This
may occur at multiple points in the cell cycle.
Figure 1 schematically represents stages in the
immune response culminating in both humoral and
cellular immune responses. Irradiation at sublethal
doses of 300 to 500 rads has variable effects on
immune responses. Its primary site of action is
probably at the level of destruction of the small
lymphocyte population which is the precursor to
events in immune proliferation. Cytotoxic drugs,
22
for example antimetabolites and biological alkylat-
ing agents, act by interfering primarily with rap-
idly dividing cells. Alkylating agents will cross-link
DNA strands. One exception is cytoxan, which
may act by interfering with antibody at the stage
of induction. Antilymphocyte sera are obtained
from animals immunized with human lymphocytes
and their main action appears to be on cell
mediated immunity rather than antibody produc-
tion. Corticosteroids are used primarily as anti-
inflammatory agents, their main effect being stabi-
lization of liposomal membranes within phagocytic
cells. However, lympholytic activities as well as
effects on T-cell-macrophage interaction have been
ascribed to this group of drugs.
In general, nonspecific immunosuppressants are
more effective at blocking the primary as com-
pared to secondary or "anamnestic" immune re-
sponse.
The use in clinical medicine of chemotherapeutic
agents with immunosuppressive activity is directed
at alleviating immunologically mediated disease,
lymphoproliferative diseases and prevention of
graft rejections following organ transplantation.
Some examples of agents useful in these respects
are shown in Table 2. However, prolonged immu-
nosuppression is dangerous: not only are the
agents highly toxic for various cells but their use is
associated with increased susceptibility to various
infections (Table 3) and to secondary malignancies.
Particularly disturbing is the increased frequency
of cancer in kidney allograft recipients. Suppres-
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Condition Example Agent
Immunologically mediated disease
Exogenous antigens Allergy steroids
Homologous antigenis Rh isoimmunization Anti Rh0, globulin
Autologous antigens Autoimmune disease Steroids
Antimetabolites
Lymphoproliferative diseases Multiple myeloma Steroids
Hodgkin's disease X-ray
Leukemia Antimetabolites
Transplantation Cardiac and renal transplants Antilymphocyte serum
Steroids
Antimetabolites
Table 3. Infections associated with chemotherapy-induced
immune suppression.
Viral
Herpesvirus infections, e.g., zoster, cytomegalovirus,
Epstein-Barr
Viral vaccines, e.g., vaccinia
Bacterial
Gram-negative organisms
Staphylococcus aureus
Fungal/yeast
Aspergillus
Candida
Malignancies of unknown etiology
Tumors in homograft recipients on immunosuppression
Second and third malignancies in leukemia or lymphoma
patients on cytotoxic therapy, particularly with biological
alkylating agents.
Carcinomas in congenital immunodeficiencies
sion of cell-mediated rather than humoral immu-
nity is thought to be primarily responsible, because
the most effective antitumor responses are believed
to be cell-mediated.
Specific Methods for
Assessment of Immunity
Because ofthe known immunosuppressive action
of many drugs used in clinical medicine, it is
becoming of increasing importance to monitor
immunologic parameters during therapy. Because
immune function can be conveniently compartmen-
talized as either "humoral" or "cellular," it is
operationally possible to assess functions in these
respects. However, it must be emphasized that
because of the interdependent nature of all immu-
nologic responses, failure to detect reactivity at
one level does not necessarily represent a primary
site of action of a particular drug or drugs. Tables
4 and 5 list some specific methods that are useful
in evaluating both humoral and cellular immunity.
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Table 4. Assessment of humoral immune functions.
Quantitation of serum immunoglobulins
Radial immunodiffusion
Serum electrophoresis
Immunoelectrophoresis
Quantitation of specific antibody
Agglutination
CF
RIA
ELISA
Specific antibody responses after immunization
B-cell quantitation by immunofluorescence and transformation
response to mitogens PWM
Table 5. Assessment of cellular immune function.
Neutrophils
Quantitation
Phagocytosis: Nitroblue tetrazolium reduction
Skin test for delayed hypersensitivity to specific antigens,
e.g., TB
T-lymphocytes
Quantitation: rosettes
Activation:
Transformation or DNA synthesis after mitogen, e.g., PHA
or specific antigen stimulation
Lymphokines, e.g., migration inhibition factor, interferon
HLA restricted cytotoxicity
More detailed descriptions of these currently used
methodologies are given elsewhere (2).
Model Systems for Studying
Effects of Immunosuppressive
Drugs in Patient Populations
At Stanford University Medical Center, there
are two large populations of immunosuppressed
patients. Patients are treated for Hodgkin's dis-
23ease, as well as other lymphoid tumors, by irradia-
tion and chemotherapy. Additionally, cardiac trans-
plants have been performed at Stanford, and to
reduce risk of graft rejection immunosuppression
must be used in this group. Because of the
frequent occurrence of infectious diseases in these
two patient populations, we have instituted a
program of prospective immunologic monitoring in
order to attempt to identify those functions which
may be useful prognostic indications of serious
disease.
Herpes zoster, caused by varicella-zoster virus
(VZ) in the treated lymphoma patients, for exam-
ple Hodgkin's disease, is a recurrent and some-
times life-threatening occurrence. The incidence of
herpes zoster in this particular patient group has
been found to be higher than that among patients
with solid tumors (3). The immunologic character-
istics of Hodgkin's disease which may predispose
to VZ infection include loss ofpre-existing delayed
hypersensitivity by skin testing as well as a loss of
ability to acquire new hypersensitivities. Lympho-
penia is present, but antibody formation is impaired
only in advanced stages, beyond the period when
zoster is most frequent. Among the patients with
zoster, a significant number will develop dissemin-
ated disease superimposed upon the initial seg-
mented lesion associated characteristically with a
particular dermatome. Therefore, two specific prob-
lems probably related to deficient cell mediated
immunity exist in this patient population: first, an
increased risk of initial VZ disease and second,
with disease occurrence, an increased frequency of
dissemination.
Studies in our laboratory have focused on two
parameters of cell-mediated immune function:
lymphocyte transformation and interferon in re-
sponses to specific herpesviral antigens. Our studies
have shown that lymphocyte transformation in this
system represents a monocyte-dependent T-lym-
phocyte response, while B-lymphocytes, with the
help of monocytes, produce interferon (4). T-
lymphocyte transformation is immune-specific, in
that only lymphocytes from individuals with sero-
logic evidence of prior exposure will respond in
vitro with increased DNA synthesis. B-lymphocyte
interferon is augmented by herpesvirus disease,
but can also be produced by lymphocytes from
nonimmune individuals (5). Because of the recog-
nized defect in cell-mediated immunity in patients
with Hodgkin's disease, we used these two param-
eters of immunocompetent cell function to assess
specific responses in vitro to VZ antigen.
In vitro lymphocyte responses to VZ antigen in
lymphoma patients, untreated or in remission,
were compared with those of normal individuals.
24
The untreated lymphoma patients showed signi-
ficantly lower responses than other populations
tested, including normals wxith histories of chicken
pox or recent zoster and lymphoma patients in
remission. The lymphocyte interferon response
was found to be lower in both untreated and
lymphoma patients in remission as compared to
normals (6). These defects were found to be
specific for VZ, since responses in both lymphoma
patient groups to herpes simplex antigen were
comparable to those of normals. Prospective stud-
ies in 86 lymphoma patients analyzing the effect of
the first 16 month's therapy upon lymphocyte
functions to specific herpes viruses showed that
more than 50% of the cases of zoster occurred in
patients treated with both radiation and chemo-
therapy. The increased frequency in this group
was accompanied by a specific defect in lympho-
cyte transformation to VZ antigen which persisted
during the observation period (7). These studies
also showed that the responses to nonspecific
mitogens and T-cell numbers recovered to the
range of normal individuals before responses to
specific herpes viral antigens.
In the cardiac transplant population, CMV infec-
tions occur almost universally with varying mani-
festations. Some of these clinical findings include
unexplained fever, pneumonitis, hepatitis, leuko-
penia and retinitis in the late period after trans-
plant. The presence of antibody may not protect
from shedding virus in throat or urine for pro-
longed periods or from destructive pathologic lesions.
In cardiac transplant patients, defects in both
lymphocyte transformation and interferon are pres-
ent during the period of greatest risk of CMV, a
finding similar to that for herpes zoster susceptibil-
ity in the lymphoma patients (8).
New forms of herpes zoster have been recently
described in which unusually prolonged zoster was
observed in patients treated with high doses of
immunosuppressive chemotherapy (9). Usually a
self-limiting disease, cases of zoster persisted in
this group for as long as 6 months. Reduction of
immunosuppressive therapy appeared to initiate
resolution of zoster lesions and halt dissemination.
Mechanism of this prolonged form ofherpes zoster
may relate to depressed cell mediated immunity in
these hosts, since depression in T-lymphocytes
was a goal of therapy in the patients studied.
These studies suggest that small reductions or
short termwithholdingofimmunosuppressive drugs
may be sufficient to allow resolution of chronic
lesions.
Despite the obvious clinical value of immuno-
suppression, the use of such drugs must be evalu-
ated both in terms of positive benefits and nega-
Environmental Health Perspectivestive effects. Better understanding of specific
immunosuppressive effects will allow their use
with minimal adverse consequences.
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